CIA
ARIA

Capital Impact Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Capital Impact Advisors’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-45,105
Closed -$282K – 266
2015
Q4 		$282K Hold
45,105
– – 0.13% 243
2015
Q3 		$263K Hold
45,105
– – 0.13% 228
2015
Q2 		$373K Hold
45,105
– – 0.17% 220
2015
Q1 		$372K Buy
+45,105
New +$333K 0.17% 221

Other funds holding ARIA

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Capital Impact Advisors's ARIA Position: Q1 2016 in Review

Capital Impact Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2016, closing a stake of 45,105 shares — an estimated $282K sold.

Capital Impact Advisors first reported a position in ARIA in Q1 2015 and held it in 4 quarters. The position peaked at $373K in Q2 2015. 162 funds tracked by Wall St. Rank hold ARIA as of Q1 2016.

  • Capital Impact Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Capital Impact Advisors sold 45,105 Ariad Pharmaceuticals Inc shares in Q1 2016, an estimated $282K.
  • Capital Impact Advisors first reported a position in Ariad Pharmaceuticals Inc in Q1 2015 and held it in 4 quarters.
  • Capital Impact Advisors's Ariad Pharmaceuticals Inc position peaked at $373K in Q2 2015.
  • 162 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2016.

Based on Capital Impact Advisors's 13F filing for Q1 2016, filed 13 Apr 2016.